Back to News
Market Impact: 0.2
SpliSense Initiates Phase 2b Trial of SPL84 in Cystic Fibrosis
Source: PR Newswire
Healthcare & Biotech
SpliSense announced a global randomized, double-blind, placebo-controlled Phase 2b trial of once-weekly inhaled SPL84 for cystic fibrosis patients receiving CFTR modulator therapy. Topline results are expected in H2 2027, creating a long-dated clinical catalyst for the company but providing no efficacy or financial data yet.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- ‘Like Kashmir’: How a toxic marble dump yard became a tourist spot in India
- Swiss firms plan to expand China investments as trade deal deepens ties
- OmniAb: A Self-Funding Option Book On 433 Partner Programs
- Regeneron: 3 Key Takeaways for Long-Term Investors
- AbbVie: 3 Key Takeaways for Long-Term Investors
- Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy?